UreA/KatA双价减毒沙门菌疫苗株抗幽门螺杆菌的免疫保护作用

目的探讨由2种幽门螺杆菌(Hp)抗原组合的双价疫苗在防治Hp感染中的作用以及减毒鼠伤寒沙门菌作为传递Hp抗原的活疫苗载体的可行性.方法PCR技术扩增尿素酶A亚单位(ureA)和过氧化氢酶(katA)基因片段,构建表达UreA/KatA融合蛋白的重组质粒,重组质粒宿主菌经IPTG诱导,用SDS-PAGE和Westernblot分析UreA/KatA的表达情况.将该重组质粒转入减毒鼠伤寒沙门菌SL3261株中构建重组口服活疫苗株,经口服免疫C57BL/6小鼠,再用Hp悉尼株进行攻击,用快速尿素酶试验和细菌定量培养对胃粘膜中Hp的定植及生长情况进行观察.结果SDS-PAGE电泳图上显示1条相对分子质量(Mr)约108×103的新生蛋白带,占细菌总蛋白的5%,并能与抗GST抗体发生特异性反应.动物实验结果显示,经UreA/KatA双价疫苗免疫的小鼠能有效防御Hp的感染.结论表达UreA/KatA融合蛋白的双价减毒沙门菌疫苗株能诱导抗Hp保护性免疫反应,有望在Hp感染及其相关性疾病的防治中发挥积极作用.     

幽门螺杆菌Catalase基因的克隆、表达及其抗原性鉴定

目的：构建含人幽门螺杆菌（Hpylori，Hp）过氧化氢酶（catalase，KatA）编码基因的重组质粒，测定、分析其核酸序列，并在E.coli中表达，研究其抗原性。方法：应用PCR技术从HpDNA染色体中扩增KatA编码基因片段，将其T-A克隆和测序，并与GenBank公布的其他Hp菌株的基因序列比较，再将目的基因插入至融合表达载体pGEX-4T-1中进行表达，用GST亲和层析对其进行纯化。纯化产物用于对29株小鼠抗Hp-全菌单克隆抗体（mAb）的鉴定及与Hp啊感染患者血清进行Western blot。结果：KatA基因全长为1 515 bp，并在GenBank上登录（No．DQ333889），与GenBank公布的其他Hp菌株的核酸的同源性为96％～97％，表达的KatA融合蛋白的相对分子质量（Mr）为85 000，29株小鼠抗Hp全菌mAb中有4株mAb是针对KatA的，表达产物可被Hp感染患者的血清特异性识别。结论：重组KatA具有较好的抗原性，为坳检测试剂和疫苗的研究奠定了基础。     

谷胱甘肽转硫酶-血小板因子4融合蛋白表达载体的构建、鉴定与表达

目的 构建谷胱甘肽转硫酶－血小板因子4（GST－PF4）融合蛋白表达载体，并研究其编码的蛋白质在大肠杆菌中的表达。方法 通过RT－PCR方法，从HL－60细胞中克隆PF4cDNA，然后克隆至载体pUC19中，序列测定后把PF4基因重组入谷胱甘肽转硫酶融合基因表达载体pGEC-4T-3中，并用IPTG诱导其在大肠杆菌中表达。结果 获得了PF4 cDNA。序列分析表明，该序列与GenBank数据库中的序列一致。重组质粒酶切鉴定表明，PF4基因已正确插入到pGEX-4T-3中。重组融合蛋白表达载体GST－PF4经IPTG诱导表达，在SDS－PAGE后得到1条蛋白表达带，相对分子质量（Mr)约为36000。结论 成功地构融合蛋白表达载体GST－PF4，并大肠杆菌中获得有效表达，为进一步研究打下良好的基础。     

细粒棘球绦虫疫苗候选分子EgA31的GST融合蛋白原核表达及纯化

目的 :构建细粒棘球绦虫疫苗候选分子EgA31重组质粒 ,表达及纯化EgA31 GST融合蛋白 ,为疫苗的研究奠定基础。方法 :PCR扩增EgA31cDNA ,将得到的cDNA经限制性内切酶酶切 ,然后亚克隆入pGEX 5X 3质粒 ,转化BL2 1宿主菌 ,IPTG诱导重组质粒的表达 ,亲和层析纯化表达产物 ,Bradford法测定重组蛋白含量 ,用SDS PAGE和Westernblot进行分析鉴定。结果 :SDS PAGE显示分离纯化的EgA31 GST融合蛋白为 4 5kDa ,测序检验重组质粒中EgA31cDNA序列正确。EgA31 GST融合蛋白免疫豚鼠得到的抗血清可与细粒棘球绦虫原头蚴总蛋白在 6 6kDa处特异性反应。结论 :EgA31 GST融合蛋白获得高效表达 ,并成功纯化 ,初步实验证明具有良好的免疫原性 ,可用于进一步疫苗的免疫注射实验     

日本血吸虫重组质粒pET32α-Sj26GST—Sj32的构建及其在大肠埃希菌BL21（DE3）中的表达

目的构建日本血吸虫重组质粒pET32α-Sj26GST—Sj32,分析该质粒在大肠埃希菌BL21（DE3）中的表达情况。方法超声粉碎日本血吸虫成虫提取总RNA,通过RT—PCR扩增获得Sj26GST和Sj32抗原编码基因,然后采用基因拼接法（geneSOEing）剪接Sj26GST和Sj32,得到Sj26GST—Sj32融合基因,克隆至原核表达载体pET32α（＋）,构建重组质粒pET32α一Sj26GST—Sj32,转化人大肠埃希菌BL21（DE3）,经异丙基硫代-β—D．半乳糖苷（IPTG）诱导表达后用SDS—PAGE和Westem—blot对表达产物进行分析和鉴定。结果基因拼接法扩增出约1991bp的Sj26GST—Sj32融合基因;双酶切和PCR鉴定证实Sj26GST—Sj32融合基因成功插入pET32α（＋）中,SDS—PAGE分析显示表达产物为分子质量约82000Mr的重组蛋白．与预期结果一致,表达的蛋白约占菌体总蛋白的22％：Western—blot鉴定重组蛋白能被日本血吸虫感染的兔血清识别。结论成功构建了日本血吸虫重组质粒pET32α一Sj26GST—Sj32,该质粒在大肠埃希菌BL21中获得了高效融合表达,表达的融合蛋白具有特异的抗原一件     

F10蛋白的原核表达及多克隆抗体的制备

目的：表达F10蛋白，并制备兔抗F10多克隆抗体。方法：利用PCR方法扩增F10基因片段，经BamHⅠ和EcoRⅠ酶切后连接人pET-GST原核表达载体，构建的pET-GST／F10融合重组表达质粒转化大肠杆菌B121，经IPTG诱导表达蛋白，并以亲和层析的方法进行纯化。表达产物用SDS—PAGE电泳和Western blot进行分析鉴定。以纯化的F10蛋白免疫新西兰大白兔，制备兔抗F10的多克隆抗体，并以ELISA法检测抗体效价。结果：经酶切和核酸序列分析证实重组质粒包含有正确编码的F10读码框。SDS—PAGE电泳分析显示pET—GST／F10诱导后表达一相对分子质量（Mr）约为61000的融合蛋白，与预期结果相符。目的蛋白纯化后的纯度达90％以上，Western blot证实该蛋白是GST／F10的融合蛋白。将纯化的GST／F10融合蛋白免疫家兔，得到的兔抗F10抗体效价达1：20000。结论：成功构建了人F10基因原核表达载体，并获得了高纯度的F10重组蛋白及兔抗F10抗体，为下一步研究F10基因功能奠定了实验基础。     

4型腺病毒疫苗株载体的构建及β-半乳糖苷酶基因的表达

目的构建缺失Ｅ３区７８．９－８６ｍｕ的４型腺病毒疫苗株载体。方法从４型腺病毒疫苗株（Ａｄ４）感染的人胚肺二倍体细胞２ＢＳ中提取病毒ＤＮＡ,经过多步亚克隆构建成功缺失７８．９－８６ｍｕ的载体。将含有ＣＭＶ早期启动子的β－半乳糖苷酶基因插入缺失部位,将这一重组质粒与Ａｄ４ＢｃｌⅠ大片段共转染２９３细胞,铺含有Ｘ－Ｇａｌ的营养琼脂,经蓝色蚀斑纯化三代,ＯＮＰＧ法测定β－半乳糖苷酶基因的表达量。结果所构建的载体能稳定地表达β－半乳糖苷酶基因。结论４型腺病毒疫苗株载体的构建为利用该病毒做为基因工程疫苗载体打下了基础。     

TRAIL胸外段基因克隆及其表达与纯化

目的；克隆TNF相关的诱导凋亡配体胞膜外段基因（the extracellular region of the human TRAIL cDNA,TPAILex），构建表达载体并在大肠杆菌DH5α中高效表达有生物学活性的TRAIL蛋白胞膜外段。方法：抗CD3McAb刺激正常人外周血淋巴细胞，用RT－PCR、巢式－PCR方法从活化的淋巴细胞中获得人TRAIL基因及其胞膜外段cDNA，并克隆到pGEM-T Easy载体中，DNA测序鉴定，将TRAIL的胞膜外段基因插入表达载体pGEX-2T，构建重组表达质粒pGEX/TRAILex，用IPTG诱导表达TRAIL蛋白的胞膜外段，GST－Agarose 4B层析柱纯化GST－TRAILex融合蛋白，Western-blot鉴定纯化产物。结果：抗CD3 McAb能诱导正常人外周血核细胞TRAIL的高表达，成功地克隆了TRAIL胞膜外段基因，构建了重组表达载体pGEX/TRAILex，IPTG诱导后得到高效表达的TRAIL蛋白胞膜外段，经12％SDS－PAGE分析，可观察到一分子量和理论值相符（约54kD）的诱导表达。Kodak软件分析表达GST－TRAIL胞膜外段融合蛋白的表达量占菌体蛋白总量的28％，进一步分析证实TRAIL蛋白的胞膜外段主要以可溶性的形式表达，用GST－Agarose 4B层析柱纯化超声破菌后的上清，每升细菌培养液可得到9.8mg纯度的95％以上的GST－Tex。Western-blot结果证实54kD的表达带可与鼠抗TRAIL McAb起特异性反应。结论：成功地克隆了人TRAIL基因，并应用基因工程技术在大肠杆菌中高效表达人TRAIL蛋白的胞膜外段，为进一步研究TRAIL的功能及其在肿瘤生物治疗中的应用奠定了基础。     

4型腺病毒疫苗株载体的构建及β—半乳糖苷酶基因的 …

目的 构建缺失Ｅ３区７８．９－８６ｍｕ的４型腺病毒疫苗株载体。方法 从４型腺病毒疫苗株感染的人胚肺二倍体细胞２ＢＳ中提取病毒ＤＮＡ,经过多卡亚克隆构建成功缺失７８．９￣８６ｍｕ的载体。将含有ＣＭＶ早期启动子的β－半乳糖苷酶基因插入缺失部位,将这一重组质粒与Ａｄ４Ｂｃｌ１大片段共转染２９３细胞,铺含有Ｘ－Ｇａｌ的营养琼脂,经蓝色斑斑纯化三代,ＯＮＰＧ法测定β－半乳糖苷酶基因的表达量。结果 所构建的载     

表达幽门螺杆菌hpaA重组减毒鼠伤寒沙门氏菌的构建和鉴定

目的：构建表达幽门螺杆菌（H.pylori)hpaA的重组减毒鼠伤寒沙门低 疫苗菌。方法：用基因工程的方法将hpaA基因克隆入原核表达质粒pTrc99A,并进行了基因测序。重组质粒经鉴定后再导入减毒鼠伤寒沙门氏菌SL3261,提取重组疫苗菌质粒,PCR和酶切鉴定,筛选阳性克隆。用SDS－PAGE电泳和Western blot进行HpaA表达和鉴定。结果：经PCR和酶切证实,构建了含hpaA的重组原核表达质粒pTrc99A-hpaA,并将后者成功转化了减毒鼠伤寒沙门氏菌。HpaA能在疫苗菌中以二聚体形式表达,HpaA量约占全菌体蛋白量的17％,Westem blot证实其有免疫原性。结论：构建了表达H.pylori hpaA的重组减毒鼠伤寒沙门氏疫苗菌,为探索制备H.pylori口服活疫苗尊定了基础。     

Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection.

Urease is an important virulence factor for gastric Helicobacter spp. To elucidate the efficacy of individual urease subunits to act as mucosal immunogens, the genes encoding the respective urease subunits (UreA and UreB) of Helicobacter pylori and Helicobacter felis were cloned in an expression vector (pMAL) and expressed in Escherichia coli cells as translational fusion proteins. The recombinant UreA and UreB proteins were purified by affinity and anion-exchange chromatography techniques and had predicted molecular masses of approximately 68 and 103 kDa, respectively. Western blotting (immunoblotting) studies indicated that the urease components of the fusion proteins were strongly immunogenic and were specifically recognized by polyclonal rabbit anti-Helicobacter sp. sera. The fusion proteins (50 micrograms) were used, in combination with a mucosal adjuvant (cholera toxin), to orogastrically immunize mice against H. felis infection. Gastric tissues from H. felis-challenged mice were assessed by the biopsy urease test and by histology. In mice immunized with recombinant H. felis UreB, 60% of animals (n = 7) were histologically negative for H. felis bacteria after challenge at 17 weeks. This compared with 25% (n = 8) for mice immunized with the heterologous H. pylori UreB antigen. Neither the homologous nor the heterologous UreA subunit elicited protective responses against H. felis infection in mice. The study demonstrated that a recombinant subunit antigen could induce an immunoprotective response against gastric Helicobacter infection.     

Diagnostic potential of parechovirus capsid proteins

To study humoral and cellular immunity against human parechovirus type 1 (HPEV1), the viral capsid proteins VP0, VP1, and VP3 were expressed and purified as glutathione S-transferase (GST)-tagged recombinant proteins. The fusion proteins were used to raise antisera in rabbits. VP0 and VP1 antisera specifically detected HPEV1-infected cells in culture by immunoperoxidase staining and immunofluorescence. Furthermore, antisera against the VP0 and VP1 proteins had neutralizing effects against HPEV1 infection. When the HPEV1 antibody titers of 20 adults and 55 children were determined by a microneutralization test, the prevalence of HPEV1 antibodies in the adult population was 96%, while 50% of children were seropositive. Selected sera were used to evaluate HPEV1 fusion proteins as antigens in an enzyme immunoassay. The VP3 capsid protein appeared to be suitable for the purpose, with specificity of 100% and sensitivity of 96% compared to the neutralization test. Furthermore, T-cell responses to the purified HPEV1 and HPEV1 capsid fusion proteins were studied in 20 adults. Sixty percent of the subjects had T-cell proliferation responses to purified HPEV1, and 90% of the subjects also had positive T-cell responses to at least one of the GST capsid proteins.     

中国旱獭去唾液酸糖蛋白受体糖基结合域的原核表达与多克隆抗体的制备

目的：构建中国旱獭去唾液酸糖蛋白受体（ASGPR）H1和H2亚基糖基识别域（CRD）的原核表达质粒，体外表达纯化后制备多克隆抗体。方法：RT-PCR扩增出中国旱獭肝组织中ASGPR CRDH1和CRDH2 cDNA，将其克隆至原核表达载体pRSET-B中，在大肠杆菌BL21（DE3）pLysS内诱导表达。用纯化的重组蛋白免疫BALB/c小鼠制备多克隆抗体，并采用酶联免疫吸附试验、Western blot及免疫组织化学检测抗体的灵敏度和特异性。结果：成功构建了中国旱獭去唾液酸糖蛋白受体H1和H2亚基糖基识别域原核表达质粒pRSET-B.CRDH1和pRSET-B.CRDH2，目的蛋白可以高效表达，用其免疫BALB/c小鼠获得了高效价的特异性多克隆抗体。结论：首次成功表达了中国旱獭去唾液酸糖蛋白受体H1和H2亚基糖基识别域多肽，且纯度高，免疫原性强，用其免疫小鼠获得的多克隆抗体特异性好、效价高，为在HBV感染模型-中国旱獭体内进行肝脏疾病的靶向治疗奠定了实验基础。     

古尔图病毒重组截短糖蛋白基因的表达及抗体的制备

目的:原核表达古尔图病毒(Guertu virus,GTV)糖蛋白截短片段(Gn、Gn1、Gn2、Gn3、Gc1和Gc2),分别纯化Gn-His、Gc1-His和Gc2-His重组蛋白并制备其多克隆抗体。方法:采用RT-PCR的方法分别扩增得到GTV DXM毒株截短糖蛋白Gn、Gn1、Gn2、Gn3、Gc1和Gc2基因片段,并将其构建到原核表达载体pET-32a(+)中,继而转化到E.coli BL21(DE3)中进行诱导表达,SDS-PAGE分析蛋白质大小。经镍柱亲和层析纯化Gn-His、Gc1-His和Gc2-His重组蛋白,用GTV阳性羊血清通过Western blot法检测重组蛋白的抗原性。用纯化的蛋白质分别免疫新西兰白兔制备抗血清,ELISA法检测血清效价。将构建的真核表达载体pcDNA3.1-Gn和pcDNA3.1-Gc1/Gc2转染至哺乳动物Vero细胞,并用间接免疫荧光法评估前述制备的兔多克隆抗体的结合活性。最后用Western blot法检测血清与重组蛋白的特异性反应能力。结果:双酶切鉴定和测序结果表明pET-32a-Gn、pET-32a-Gn1/Gn2/Gn3、pET-32a-Gc1/Gc2、pcDNA3.1-Gn和pcDNA3.1-Gc1/Gc2重组表达载体构建正确,重组表达蛋白Gn-His、Gn1/Gn2/Gn3-His、Gc1/Gc2-His相对分子质量(Mr)大小分别约为63.4×103、37.1×103、31.9×103、30.8×103、40×103和54.4×103。重组表达蛋白能够被GTV阳性羊血清所识别;获得的抗GTV Gn、Gc1和Gc2兔多克隆抗体效价分别为1∶409600、1∶204800和1∶6400。间接免疫荧光检测和Western blot结果表明制备的多克隆抗体能够与真核表达产物或重组蛋白发生特异性反应。结论:重组GTV糖蛋白Gn-His、Gc1-His和Gc2-His得到了高效表达和纯化,具有较好的免疫性。制备的多克隆抗体效价高,特异性好。本研究结果为进一步开展GTV糖蛋白生物学功能及其检测方法和疫苗研究提供参考资料。     

Maturation of IgG avidity to individual rubella virus structural proteins.

BACKGROUND: the structural proteins of rubella virus, the capsid protein C and the envelope glycoproteins E1 and E2 were produced in lepidopteran insect cells using baculovirus expression vectors. The C-terminal ends of the corresponding proteins were fused to a polyhistidine tag for easy and gentle purification by metal ion affinity chromatography. OBJECTIVES: to investigate the maturation of natural and vaccinal IgG avidity against individual authentic and recombinant rubella virus (RV) structural proteins. STUDY DESIGN: the analysis was carried out using a modified immunoblotting technique where the purified baculovirus-expressed proteins were compared with authentic rubella virus proteins. Altogether, 47 well-characterised serum samples from both naturally infected patients and vaccines were studied. RESULTS: after natural RV infection, IgG antibodies specific for the E1 protein were predominant not only in terms of levels, but also in terms of rate and magnitude of avidity maturation. The avidity development of the IgG antibodies was much slower in vaccines than in patients after a natural RV infection. CONCLUSIONS: together, our results indicate that IgG avidity determination in conjunction with immunoblot analysis is useful in the diagnosis of a RV infection. The recombinant proteins showed similar reactivity patterns in the immunoblot analyses as compared with the authentic viral structural proteins, suggesting suitability for serodiagnostics.     

Development of a peptide ELISA to discriminate vaccine-induced immunity from natural infection of hepatitis A virus in a phase IV study

Hepatitis A virus (HAV) is a highly infectious agent that causes acute liver disease. The infection can trigger the production of antibodies against the structural and non-structural proteins of HAV. Nonetheless, vaccination with an HAV vaccine leads to the production of a primary antibody against the structural proteins. Because the non-structural proteins are only produced during active virus replication, there is no or very little antibody production against the non-structural proteins. However, the current commercial immunoassay cannot distinguish between antibodies produced during natural infection and those from vaccination against HAV. In our study, six immune-dominant epitopes from the non-structural proteins were designed, synthesized, linked together and cloned into pGEX-5X-1 plasmid. The recombinant protein was expressed in E. coli and purified by Ni²⁺-coated magnetic agarose beads. Then the purified recombinant protein was used as an ELISA antigen to detect antibodies for HAV non-structural proteins in serum samples. Seventy-seven attenuated and 89 inactivated vaccinated samples collected from our previous phase IV study of HAV vaccines were detected by peptide ELISA developed in this study. The mean OD₄₅₀ value for the vaccination samples and acute infection samples were 0.529 (0.486 for the attenuated group and 0.567 for the inactivated group) and 1.187, respectively. According to the receiver operating characteristic (ROC) curve, the sensitivity and specificity of the peptide ELISA were 93.80% and 91.00%, respectively. This peptide ELISA was confirmed to discriminate vaccine-induced immunity from natural infection of HAV in a phase IV study with high sensitivity and specificity.     

表达HIV-1 gag-pol△和gp 140 TM蛋白复制缺陷型重组腺病毒的构建及免疫效果研究

目的构建表达人免疫缺陷病毒Ⅰ型gag-pol△和gp140TM基因的非复制型重组腺病毒.方法首先将HIV-1的gag-pol△和gp140TM基因插入穿梭载体,再与腺病毒骨架质粒pAdEasy-1共转化E.coli BJ5183,获得重组子.转化293细胞后获得重组病毒.重组腺病毒与DNA疫苗联合免疫小鼠,ELISA检测小鼠血清中的抗体.结果获得两株重组腺病毒vAd-gag-pol△和vAd-gp140TM,能正确表达Gp140TM、Gag蛋白以及经剪切加工的P24蛋白,与DNA疫苗联合免疫小鼠后能产生高滴度的HIV-1特异性的抗体.结论成功构建了表达HIV-1结构基因的重组腺病毒,能有效诱导HIV-1特异性抗体.     

HIV-1核心蛋白p24在大肠杆菌中的表达与纯化

探索进一步提高ＨＩＶ－１Ｐ２４ｇａｇ蛋白在大肠杆菌中的表达效率,增加产物的纯化手段。方法：通过改造原核表达载体ＰＢＶ２２０和ｐＥＴ２８,构建了一种通用型温控原核表达载体ｐＶＶ５,将ＨＩＶ－１ｇａｇ基因的１１４８－１８５７编码序列,插入到ｐＶＶ５ｂ和ｐＥＴ２８ｂ的相应位点中,构建了重组表达质粒,ｐＥＧ１ｂ和ｐＥＧ７ｂ,转化到大肠杆菌中进行表达,产物利用ＩＭＡＣ金属螯合层析柱进行纯经,纯化的表达产物用